Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients
Introduction Paliperidone palmitate 1-month (PP1M) is a Long-acting injectable antipsychotic formulation, approved for the treatment of schizophrenia and schizoaffective disorder. Recently, paliperidone palmitate 3-months (PP3M) formulation was introduced, which maintains stability while offering a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2022-06-01
|
| Series: | European Psychiatry |
| Subjects: | |
| Online Access: | https://www.cambridge.org/core/product/identifier/S0924933822018867/type/journal_article |
| _version_ | 1827753549361053696 |
|---|---|
| author | P. Escobedo-Aedo J. Merayo-Cano L. Mata Iturralde L. Muñoz Lorenzo S. Ovejero S. Sánchez Alonso |
| author_facet | P. Escobedo-Aedo J. Merayo-Cano L. Mata Iturralde L. Muñoz Lorenzo S. Ovejero S. Sánchez Alonso |
| author_sort | P. Escobedo-Aedo |
| collection | DOAJ |
| description |
Introduction
Paliperidone palmitate 1-month (PP1M) is a Long-acting injectable antipsychotic formulation, approved for the treatment of schizophrenia and schizoaffective disorder. Recently, paliperidone palmitate 3-months (PP3M) formulation was introduced, which maintains stability while offering a longer dosing interval for the maintenance treatment in patients previously treated with PP1M. Despite of this, many patients are treated with PP1M without transition to PP3M.
Objectives
To identify variables explaining maintenance of PP1M treatment instead of going to PP3M. We hypothesize that more severe patients are delayed in transition to PP3M because of expectation to complete stabilization.
Methods
A descriptive analysis of 123 patients, diagnosed with psychotic disorders, on treatment with paliperidone palmitate 1 month or 3 months, was performed. Age, sex, type of paliperidone treatment, hospitalizations after the initiaton of treatment, years since diagnosis, polytherapy and toxic habits were some of the variables measured and compared between both groups (PP1M and PP3M).
Results
Most of patients (63,41%) were on PP3M. Both groups shared characteristics like male sex predominance, schizophrenia as the most common diagnosis, having a recent onset diagnosis, same frequency of polypharmacy and same pattern of drug consumption. There was a slight difference between both groups regarding severity. PP1M and PP3M showed respectively 33% and 16,7% of admissions after initiation.
Conclusions
No clear pattern determines less transition to PP3M from PP1M. No statistical difference was found except form the difference found in admission after change of treatment (to PP1M or PP3M), which could reflect influence of severity in treatment. Future research is needed in order to better elucidate this association.
Disclosure
No significant relationships.
|
| first_indexed | 2024-03-11T07:36:52Z |
| format | Article |
| id | doaj.art-532c35ab93454238b71a9bdbc6cd9c60 |
| institution | Directory Open Access Journal |
| issn | 0924-9338 1778-3585 |
| language | English |
| last_indexed | 2024-03-11T07:36:52Z |
| publishDate | 2022-06-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | European Psychiatry |
| spelling | doaj.art-532c35ab93454238b71a9bdbc6cd9c602023-11-17T05:09:14ZengCambridge University PressEuropean Psychiatry0924-93381778-35852022-06-0165S730S73110.1192/j.eurpsy.2022.1886Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patientsP. Escobedo-Aedo0J. Merayo-Cano1L. Mata Iturralde2L. Muñoz Lorenzo3S. Ovejero4S. Sánchez Alonso5Hospital Universitario Fundación Jiménez Díaz, Psychiatry, Madrid, SpainHospital Universitario Fundación Jiménez Díaz, Psychiatry, Madrid, SpainHospital Universitario Fundación Jiménez Díaz, Psychiatry, Madrid, SpainHospital Universitario Fundación Jiménez Díaz, Psychiatry, Madrid, SpainHospital Universitario Fundación Jiménez Díaz, Psychiatry, Madrid, SpainHospital Universitario Fundación Jiménez Díaz, Psychiatry, Madrid, Spain Introduction Paliperidone palmitate 1-month (PP1M) is a Long-acting injectable antipsychotic formulation, approved for the treatment of schizophrenia and schizoaffective disorder. Recently, paliperidone palmitate 3-months (PP3M) formulation was introduced, which maintains stability while offering a longer dosing interval for the maintenance treatment in patients previously treated with PP1M. Despite of this, many patients are treated with PP1M without transition to PP3M. Objectives To identify variables explaining maintenance of PP1M treatment instead of going to PP3M. We hypothesize that more severe patients are delayed in transition to PP3M because of expectation to complete stabilization. Methods A descriptive analysis of 123 patients, diagnosed with psychotic disorders, on treatment with paliperidone palmitate 1 month or 3 months, was performed. Age, sex, type of paliperidone treatment, hospitalizations after the initiaton of treatment, years since diagnosis, polytherapy and toxic habits were some of the variables measured and compared between both groups (PP1M and PP3M). Results Most of patients (63,41%) were on PP3M. Both groups shared characteristics like male sex predominance, schizophrenia as the most common diagnosis, having a recent onset diagnosis, same frequency of polypharmacy and same pattern of drug consumption. There was a slight difference between both groups regarding severity. PP1M and PP3M showed respectively 33% and 16,7% of admissions after initiation. Conclusions No clear pattern determines less transition to PP3M from PP1M. No statistical difference was found except form the difference found in admission after change of treatment (to PP1M or PP3M), which could reflect influence of severity in treatment. Future research is needed in order to better elucidate this association. Disclosure No significant relationships. https://www.cambridge.org/core/product/identifier/S0924933822018867/type/journal_articlePaliperidone palmitateseverityLong-acting inyectableTreatment |
| spellingShingle | P. Escobedo-Aedo J. Merayo-Cano L. Mata Iturralde L. Muñoz Lorenzo S. Ovejero S. Sánchez Alonso Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients European Psychiatry Paliperidone palmitate severity Long-acting inyectable Treatment |
| title | Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients |
| title_full | Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients |
| title_fullStr | Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients |
| title_full_unstemmed | Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients |
| title_short | Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients |
| title_sort | differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice with psychotic patients |
| topic | Paliperidone palmitate severity Long-acting inyectable Treatment |
| url | https://www.cambridge.org/core/product/identifier/S0924933822018867/type/journal_article |
| work_keys_str_mv | AT pescobedoaedo differencesofusebetweenpaliperidonepalmitate3monthandpaliperidonepalmitate1monthinrealpracticewithpsychoticpatients AT jmerayocano differencesofusebetweenpaliperidonepalmitate3monthandpaliperidonepalmitate1monthinrealpracticewithpsychoticpatients AT lmataiturralde differencesofusebetweenpaliperidonepalmitate3monthandpaliperidonepalmitate1monthinrealpracticewithpsychoticpatients AT lmunozlorenzo differencesofusebetweenpaliperidonepalmitate3monthandpaliperidonepalmitate1monthinrealpracticewithpsychoticpatients AT sovejero differencesofusebetweenpaliperidonepalmitate3monthandpaliperidonepalmitate1monthinrealpracticewithpsychoticpatients AT ssanchezalonso differencesofusebetweenpaliperidonepalmitate3monthandpaliperidonepalmitate1monthinrealpracticewithpsychoticpatients |